TOP10 antidepressants reshuffle!

According to the latest data from Mi Nei.

The ranking of the antidepressant TO P10 has changed! Pfizer, Eli Lilly, and Lingbei "iron triangle" are broken

Sales of terminal antidepressant drugs in public medical institutions in China in recent years

Source: Terminal competition landscape of China's public medical institutions

Depression is a common mental illness, and it has become a major public health and social problem

From the perspective of the sales structure of manufacturers, the TOP3 "iron triangle" situation composed of Pfizer, Eli Lilly and Ling Bei has been broken for many years, and the total market share has fallen from more than 35% in 2020 to 26% in the first half of 2021.

2021H1 TOP10 Terminal Antidepressant Drug Products in Public Medical Institutions in China

Source: Terminal competition landscape of China's public medical institutions

The sales of TOP10 products all exceeded 100 million yuan, and escitalopram oxalate tablets still ranked first

In the five batches of centralized procurement carried out by the country, a total of 8 antidepressants have been included, including escitalopram oxalate tablets, sertraline hydrochloride tablets, duloxetine hydrochloride enteric-coated capsules, and paroxetine hydrochloride tablets , Venlafaxine Hydrochloride Sustained-Release Capsules and Venlafaxine Hydrochloride Sustained-Release Tablets are among the top 10 terminal antidepressant products in China's public medical institutions in the first half of 2021

Except for the two varieties of venlafaxine hydrochloride sustained-release capsules and venlafaxine hydrochloride sustained-release tablets, which have just begun to land in the fifth batch of centralized procurement, only escitalopram oxalate tablets (4+7, expanded centralized procurement) ) Is a positive growth.

In the domestic antidepressant market, due to the early entry of original research drugs, the top position has been occupied by foreign pharmaceutical companies for many years

18 antidepressants have been reviewed, Fosun, Kelun.

Source: One-key search on Mynet, MED2.

Up to now, a total of 18 antidepressants have been reviewed.

In terms of the number of products reviewed, Fosun Pharma, Kelun Pharmaceutical, and Huahai Pharmaceutical lead the way

16 antidepressants are under review! Luye Class 1 new drugs, Renfu, Kanghong.

Source: Meinenet MED2.

Since 2019, a total of 16 antidepressant drugs have been reported for production and are under review and approval.

Ansufaxine Hydrochloride Sustained-Release Tablets is a new class 1 drug developed by Luye Pharma, and a new antidepressant drug developed based on its new therapeutic entity/new molecular entity (NTE/NCE) technology platform
.
According to data, in March this year, Luye Pharma’s new compound (NCE) and Ansufaxine Hydrochloride Sustained-Release Tablets (LY03005) for the treatment of depression (MDD) in the China III clinical trial reached the preset end point; in June, LY03005’s The listing application was accepted by CDE
.

In addition, escitalopram oxalate oral solution, desvenlafaxine succinate sustained-release tablets, fluoxetine hydrochloride oral solution and other products have not been approved by enterprises, involving Chengdu Kanghong Pharmaceutical | Chengdu Dikang Pharmaceutical, Zhejiang Guojing Pharmaceutical, Zhejiang Jianfeng Pharmaceutical, Yichang Renfu Pharmaceutical and many other companies
.

Source: Mi Neiwang database

If there is any omission, please correct me!